Search results for "Cardiac Catheterization"

showing 10 items of 69 documents

5-Year Experience of In-Hospital Outcomes After Percutaneous Left Atrial Appendage Closure in Germany

2019

The aim of this study was to evaluate 5-year in-hospital trends and safety outcomes of left atrial appendage (LAA) closure in the German nationwide inpatient sample.The safety and efficacy of percutaneous LAA closure have been demonstrated in randomized trials and prospective cohort studies, but results from large samples are missing.Data on patient characteristics and in-hospital safety outcomes for all percutaneous LAA closures performed in Germany between 2011 and 2015 were analyzed. Overall, 15,895 inpatients were included.The annual number of LAA occlusions increased from 1,347 in 2011 to 4,932 in 2015 (β = 1.00; 95% confidence interval [CI]: 0.95 to 1.01; p 0.001), with a nonsignifica…

MaleCardiac Catheterizationmedicine.medical_specialtyTime FactorsPercutaneousHealth StatusComorbidity030204 cardiovascular system & hematologyPericardial effusionlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialRisk FactorslawCause of DeathGermanyAtrial FibrillationHumansMedicineAtrial AppendageHospital Mortality030212 general & internal medicineProspective cohort studyStrokeAgedAged 80 and overbusiness.industryMortality rateAtrial fibrillationmedicine.diseaseConfidence intervalSurgeryTreatment OutcomeAtrial Function LeftFemaleCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Interventions
researchProduct

12‐Month outcomes of transcatheter tricuspid valve repair with the PASCAL system for severe tricuspid regurgitation

2021

Objectives We investigated the durability of tricuspid regurgitation (TR) reduction and the clinical outcomes through 12 months after transcatheter tricuspid valve repair (TTVr) with the PASCAL Transcatheter Valve Repair System. Background TTVr has rapidly developed and demonstrated favorable acute outcomes, but longer follow-up data are needed. Methods Overall, 30 patients (age 77 ± 6 years; 57% female) received PASCAL implantation from September 2017 to May 2019 and completed a clinical follow-up at 12 months. Results The TR etiology was functional in 25 patients (83%), degenerative in three (10%), and mixed in two (7%). All patients had TR severe or greater (massive or torrential in 80%)…

MaleCardiac Catheterizationmedicine.medical_specialtyTime FactorsRegurgitation (circulation)030204 cardiovascular system & hematologytranscatheter tricuspid valve intervention PASCAL 12-month outcomes severe tricuspid regurgitation right-sided heart failure03 medical and health sciences0302 clinical medicinemedicineHumansEndocarditisRadiology Nuclear Medicine and imagingddc:610030212 general & internal medicineTRICUSPID VALVE REPAIRStrokeSurvival rateAgedAged 80 and overHeart Valve Prosthesis Implantationbusiness.industryPascal (unit)General Medicinemedicine.diseaseTricuspid Valve InsufficiencySurgeryTreatment OutcomeHeart failureEtiologyFemaleTricuspid ValveCardiology and Cardiovascular MedicinebusinessCatheterization and Cardiovascular Interventions
researchProduct

Value of Echocardiographic Right Ventricular and Pulmonary Pressure Assessment in Predicting Transcatheter Tricuspid Repair Outcome

2020

The aim of this study was to assess the value of echocardiographic right ventricular (RV) and systolic pulmonary artery pressure (sPAP) assessment in predicting transcatheter tricuspid edge-to-edge valve repair (TTVR) outcome.RV dysfunction and pulmonary hypertension are associated with poor prognosis and are systematically sought during tricuspid regurgitation evaluation. The value of echocardiographic assessment in predicting TTVR outcome is unknown.Data were taken from the TriValve (Transcatheter Tricuspid Valve Therapies) registry, which includes patients undergoing TTVR at 14 European and North American centers. The primary outcome was 1-year survival free from hospitalization for hear…

MaleCardiac Catheterizationmedicine.medical_specialtyTime FactorsRegurgitation (circulation)Pulmonary Artery030204 cardiovascular system & hematologySeverity of Illness Index03 medical and health sciences0302 clinical medicinePrimary outcomePredictive Value of TestsInternal medicinemedicine.arteryVentricular PressureHumansMedicineArterial PressureProspective StudiesRegistries030212 general & internal medicineAgedAged 80 and overHeart FailureHospital readmissionTricuspid valvebusiness.industryRecovery of FunctionMiddle Agedmedicine.diseasePulmonary hypertensionTricuspid Valve Insufficiency3. Good healthPulmonary pressureEuropeTreatment Outcomemedicine.anatomical_structureEchocardiographyHeart failureNorth AmericaPulmonary arteryDisease ProgressionVentricular Function RightCardiologyFemaleCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Interventions
researchProduct

Predictors of short‐ and long‐term outcomes of patients undergoing transcatheter mitral valve edge‐to‐edge repair

2020

Objectives Transcatheter mitral valve repair (TMVR) by edge-to-edge therapy is an established treatment for severe mitral valve regurgitation (MR). Background Symptomatic and prognostic benefit in functional MR has been shown recently; nevertheless, data on long-term outcomes are sparse. Methods and results We analyzed survival of patients treated with isolated edge-to-edge repair from June 2010 to March 2018 (primarily combined edge-to-edge repair with other mitral valve interventions was excluded) in a retrospective monocentric study. Overall, 627 consecutive patients (47.0% females, 78.6 years in mean) were included. Leading etiology was functional MR (57.4%). Follow-up regarding surviva…

MaleCardiac Catheterizationmedicine.medical_specialtymedicine.medical_treatmentDischarged alive030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineMitral valveLong term outcomesmedicineHumansRadiology Nuclear Medicine and imaging030212 general & internal medicineRetrospective StudiesHeart Valve Prosthesis ImplantationCOPDMitral valve repairMitral regurgitationbusiness.industryMitral Valve InsufficiencyGeneral Medicinemedicine.diseaseSurgeryTreatment Outcomemedicine.anatomical_structureEtiologyMitral ValveFemaleCardiology and Cardiovascular MedicineMitral valve regurgitationbusinessCatheterization and Cardiovascular Interventions
researchProduct

Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspect…

2015

International audience; AIMS: In symptomatic patients with suspected coronary artery disease (CAD), computed tomographic angiography (CTA) improves patient selection for invasive coronary angiography (ICA) compared with functional testing. The impact of measuring fractional flow reserve by CTA (FFRCT) is unknown. METHODS AND RESULTS: At 11 sites, 584 patients with new onset chest pain were prospectively assigned to receive either usual testing (n = 287) or CTA/FFR(CT) (n = 297). Test interpretation and care decisions were made by the clinical care team. The primary endpoint was the percentage of those with planned ICA in whom no significant obstructive CAD (no stenosis \textgreater/=50% by …

MaleCardiac Catheterizationmedicine.medical_specialtymedicine.medical_treatment[SDV]Life Sciences [q-bio]Myocardial InfarctionCoronary Artery DiseaseFractional flow reserveUnnecessary ProceduresCoronary AngiographyChest painCoronary artery diseaseAnginaInternal medicineMyocardial RevascularizationHumansMedicineAngina StableLongitudinal StudiesProspective StudiesMyocardial infarctioncardiovascular diseasesCardiac catheterizationmedicine.diagnostic_testbusiness.industrySurrogate endpointPatient SelectionMiddle Agedmedicine.disease3. Good healthddc:Fractional Flow Reserve MyocardialHospitalizationAngiographyCardiologyFeasibility StudiesFemaleRadiologymedicine.symptomTomography X-Ray ComputedCardiology and Cardiovascular Medicinebusiness
researchProduct

Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study.

2020

Background: Percutaneous left atrial appendage closure (LAAC) exposes to the risk of device thrombosis in patients with atrial fibrillation who frequently have a contraindication to full anticoagulation. Thereby, dual antiplatelet therapy (DAPT) is usually preferred. No randomized study has evaluated nonvitamin K antagonist oral anticoagulant after LAAC, and we decided to evaluate the efficacy and safety of reduced doses of rivaroxaban after LAAC. Methods: ADRIFT (Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban in Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure) is a multicenter, phase IIb study, which randomized 105 patients after successful LAAC to eith…

Malemedicine.medical_specialtyCardiac CatheterizationPercutaneousTime FactorsAntithrombin IIIAtrial AppendagePilot Projects030204 cardiovascular system & hematologyFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRivaroxabanLeft atrialHeart RateInternal medicineAtrial FibrillationMedicineHumansAtrial Appendage030212 general & internal medicineContraindicationBlood CoagulationAgedAppendageAged 80 and overRivaroxabanbusiness.industryDual Anti-Platelet TherapyAtrial fibrillationThrombosisClopidogrelmedicine.diseasePeptide Fragments3. Good healthTreatment OutcomeCardiologyAtrial Function LeftFemaleProthrombinFranceCardiology and Cardiovascular MedicinebusinessBiomarkersPlatelet Aggregation Inhibitorsmedicine.drugFactor Xa InhibitorsPeptide HydrolasesCirculation. Cardiovascular interventions
researchProduct

Percutaneous closure of left atrial appendage to prevent embolic events in high-risk patients with chronic atrial fibrillation

2009

Background: Percutaneous closure of the left atrial appendage (LAA) is a novel alternative for the treatment of patients with atrial fibrillation (AF) and with a high risk of stroke who are not eligible for long-term anticoagulation therapy. The aim of this study was to asses the safety, feasibility, and long-term efficacy of this procedure. Methods: From July 2004 to June 2007, 20 patients (13 male, mean age 69 ± 8 years) with non–valvular AF (NV-AF) underwent LAA percutaneous closure using the PLAATO™ system, implanted through a transeptal access. All patients had contraindications to anticoagulant therapy and were at high risk for cardioembolic stroke (mean CHADS2 score 3 ± 1.2). A trans…

Malemedicine.medical_specialtyCardiac CatheterizationPercutaneousTime FactorsThromboembolism.left atrial appendage occlusionmedicine.medical_treatmentEmbolismSettore MED/11 - Malattie dell'Apparato CardiovascolareTransesophagealLeft atrial appendage occlusionPericardial effusionRisk AssessmentLeft atrialInternal medicineAtrial FibrillationmedicineHumansRadiology Nuclear Medicine and imagingAtrial Appendageatrial fibrillation; left atrial appendage occlusion; thromboembolism; Aged; Atrial Fibrillation; Contraindications; Echocardiography Transesophageal; Embolism; Equipment Design; Feasibility Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Assessment; Stroke; Time Factors; Treatment Outcome; Anticoagulants; Atrial Appendage; Cardiac Catheterization; Chronic DiseaseStrokeAgedbusiness.industryContraindicationsAnticoagulantsAtrial fibrillationGeneral MedicineEquipment DesignthromboembolismMiddle Agedmedicine.diseaseSurgeryStrokeTreatment OutcomePericardiocentesisEchocardiographyChronic DiseaseCardiologyPatent foramen ovaleFeasibility StudiesFemaleCardiology and Cardiovascular MedicinebusinessEchocardiography TransesophagealPlatelet Aggregation Inhibitors
researchProduct

Tumor Marker Carbohydrate Antigen 125 Predicts Adverse Outcome After Transcatheter Aortic Valve Implantation

2013

ObjectivesThis study sought to predict the value of tumor marker carbohydrate antigen 125 (CA125) before and after transcatheter aortic valve implantation (TAVI) for all-cause death and a composite endpoint of death, admission for heart failure, myocardial infarction, and stroke (major adverse cardiac events [MACE]).BackgroundRisk stratification after TAVI remains challenging. The use of biomarkers in this setting represents an unmet need.MethodsCA125 was measured in 228 patients before and after TAVI. The association with outcomes was assessed using parametric Cox regression and joint modeling for baseline and longitudinal analyses, respectively. CA125 was evaluated as logarithm transforma…

Malemedicine.medical_specialtyCardiac CatheterizationTime FactorsAortic Valve InsufficiencyMyocardial InfarctionKaplan-Meier EstimateRisk AssessmentCA125Interquartile rangeRisk FactorsInternal medicineMedicineHumansMyocardial infarctionLongitudinal StudiesRegistriesStroketranscatheter aortic valve implantationTumor markerAgedProportional Hazards ModelsAged 80 and overHeart FailureHeart Valve Prosthesis ImplantationProportional hazards modelbusiness.industryMembrane ProteinsAortic Valve Stenosismedicine.diseasejoint modelingHospitalizationStrokeLogistic ModelsTreatment OutcomeCardiovascular DiseasesHeart failureCA-125 AntigenMultivariate AnalysisCardiologybiomarkerBiomarker (medicine)FemaleprognosisbusinessCardiology and Cardiovascular MedicineMaceBiomarkersJACC: Cardiovascular Interventions
researchProduct

Long-term beneficial effects of PTCA on segmental early relaxation in disease of the left anterior descending coronary artery.

1988

The relationship between regional left ventricular (LV) motion and global pressure relaxation of the left ventricle remains unclear. To clarify the recent concept of segmental early relaxation in coro nary artery disease, the authors in vestigated two groups of patients. In group I, all 12 patients (mean age 47±7 years) exhibited evidence of a normal heart after an extensive in vestigation. In group II, 25 patients (55±7 years) presented an isolated stenosis of the left anterior descend ing coronary artery, and they under went a hemodynamic investigation before and after (six to nine months) a durable successful percutaneous transluminal coronary angioplasty (PTCA). After all conventional …

Malemedicine.medical_specialtyCardiac CatheterizationTime FactorsHeart VentriclesHemodynamicsCoronary Disease030204 cardiovascular system & hematologyAnterior Descending Coronary Artery03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineBeneficial effectsRelaxation (psychology)business.industryHemodynamicsMiddle Agedmedicine.diseaseMyocardial ContractionSurgeryStenosismedicine.anatomical_structureVentricleCoronary vesselCardiologyFemaleCardiology and Cardiovascular MedicinebusinessAngioplasty BalloonArteryFollow-Up StudiesAngiology
researchProduct

Cardiopulmonary Hemodynamic Profile Predicts Mortality After Transcatheter Tricuspid Valve Repair in Chronic Heart Failure.

2020

This study was designed to assess hemodynamic changes in response to transcatheter tricuspid valve edge-to-edge repair (TTVR) and to identify hemodynamic predictors associated with mortality.Severe tricuspid regurgitation (TR) is associated with high mortality. TTVR effectively alleviates heart failure symptoms, but comprehensive hemodynamic characterization of patients undergoing TTVR is currently lacking.This international, multicenter study included 236 patients undergoing TTVR. Data from clinical assessment, echocardiography, intraprocedural right heart catheterization, and noninvasive cardiac output measurement were analyzed. Hemodynamic predictors for mortality were identified using l…

Malemedicine.medical_specialtyCardiac CatheterizationTime FactorsHemodynamicsRegurgitation (circulation)030204 cardiovascular system & hematologyNew york heart association03 medical and health sciences0302 clinical medicineInternal medicineMedicineHumans030212 general & internal medicineTRICUSPID VALVE REPAIRAgedHeart FailureHeart Valve Prosthesis ImplantationTricuspid valvebusiness.industryProportional hazards modelHemodynamicsRecovery of Functionmedicine.diseaseTricuspid Valve Insufficiencymedicine.anatomical_structureTreatment OutcomeMulticenter studyHeart failureCardiologyFemaleTricuspid ValveCardiology and Cardiovascular MedicinebusinessJACC. Cardiovascular interventions
researchProduct